Mirati Therapeutics Inc., of San Diego, raised gross proceeds of $234.2 million in a now-closed underwritten public offering of about 2.4 million common shares priced at $97 each. Underwriters of the offering exercised in full their option to purchase up to 315,000 additional shares. Cowen, Credit Suisse and Barclays acted as joint book-running managers.

Carrick Therapeutics Ltd., of Dublin, said it plans to establish business operations in Boston, and made public the transition of CEO leadership from Elaine Sullivan, based in Dublin, to Tim Pearson, based in Boston.